Mortality after CABG versus PCIIndividual patient-data pooled analysis of 11,518 patients from 11 randomized trials

Stuart Head and Pieter Kappetein

Dept Cardio-thoracic Surgery Erasmus University Medical Center Rotterdam, The Netherlands

#### On behalf of:

Milan Milojevic, MD, MSc<sup>1</sup> Joost Daemen, MD PhD; Jung-Min Ahn, MD; Professor Eric Boersma, PhD<sup>2</sup>; Evald H. Christiansen, MD PhD<sup>4</sup>; Professor Michael J. Domanski, MD<sup>5, 6</sup>; Michael E. Farkouh, MD PhD<sup>5, 6</sup>; Professor Marcus Flather, MD PhD<sup>7</sup>; Valentin Fuster, MD, PhD<sup>5</sup>; Grigorios Papageorgiou, MSc<sup>1, 8</sup>; Niels R. Holm, MD<sup>4</sup>; Professor Mark A. Hlatky, MD<sup>9</sup>; Whady A. Hueb, MD<sup>1b</sup>; Masoor Kamalesh, MD<sup>11</sup>; Young-Hak Kim, MD<sup>3</sup>; Timo Mäkikallio, MD<sup>12</sup>; Professor Friedrich W. Mohr, MD PhD<sup>13</sup>; Seung-Jung Park, MD<sup>3</sup>; Alfredo E. Rodriguez, MD PhD<sup>14</sup>; Joseph F. Sabik III, MD<sup>15</sup>; Rodney H. Stables, MD<sup>16</sup>; Gregg W. Stone, MD; Professor Patrick W. Serruys, MD PhD





#### **Disclosure Statement of Financial Interest**

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

#### **Affiliation/Financial Relationship**

Employee

- Company
- Medtronic







Numerous trial have compared CABG and PCI

Multi-vessel disease

Left Main disease







## No studies have been powered to detect a difference in Mortality or Stroke







## **Patients**



#### **Baseline Characteristics**

	PCI (n=5753)	CABG (n=5765)
Age	64 ± 9·8	$64 \pm 9.9$
Female sex	24%	24%
Diabetes	39%	38%
Insulin treated	13%	12%
Previous TIA or CVA	5%	6%
Previous MI	28%	28%
Moderate LVEF (30-49%)	15%	14%
Poor LVEF (<30%)	1%	1%
Three-vessel disease	59%	61%
Left main disease	39%	39%





# **Procedure Characteristics**

PCI – stents*		-
BMS	27%	-
DES	73%	_
First-generation DES	39%	-
Newer-generation DES	34%	-
PCI – number of stents	3•1 ± 2•	0 -
CABG = LIMA use	-	96%
CABG – BIMA use	-	19%
CABG – off-pump	-	28%






# Mortality Results

5 year overall


<b>†</b> PCI: 11·2%	
<b>†</b> CABG: 9.2%	→P=0.0038
<b>†</b> PCI: 11·5%	
<b>†</b> CABG: 8⋅9%	→ P=0.0019
<b>†</b> PCI: 10·7%	
<b>†</b> CABG: 10·5%	→ P=0.52

#### **Overall Mortality PCI versus CABG**



t2017







## **Subgroup analysis**


isk     Male   387/4380 (10-7)   318/4394 (8-8)   1-20 (1-031-33)   0.0181   0.42     Female   152/1373 (12-7)   119/1371 (10-6)   1-23 (10-97-157)   0.0854   0.98     465   200/2971 (8-0)   160/2940 (6-4)   1-23 (10-01-51)   0.0534   0.98     655 or older   339/2782 (14-8)   277/2825 (12-5)   119 (10-21-40)   0.0284     300 mass index		PCI	CABG				Interaction
Male   387/4380 (10.7)   318/4394 (8.8)   Image   120 (10-31-39)   0.0131   0.82     Female   123 (10-71-57)   0.0854   0.0131   0.0231   0.0231   0.0231     Ge   300/2371 (8:0)   160/2340 (6:4)   Image   123 (10-01-150)   0.0534   0.0334   0.0334     G5   0.012/371 (8:0)   160/2340 (6:4)   Image   120 (10-01-140)   0.024   0.0155     G40   393/73958 (11-2)   304/3953 (9:4)   Image   120 (10-01-140)   0.017   0.017     S00 more   148/1548 (12.1)   106/1558 (8:6)   Image   1135 (10-01-140)   0.027   0.025     No   137/13580 (12.2)   32/3913 (10-6)   Image   1136 (10-01-140)   0.027   0.026     Vest   364/3982 (11-0)   288/3862 (9:1)   1337 (10-01-76)   0.027   0.027   0.026     No   278/2215 (15-7)   185/2171 (10-7)   Image   124 (10-01-150)   0.027   0.026     No   288/32 (130)   252/3594 (8:4)   123 (10-61-76)   0.0452   0.076   0.076     No   218/2070 (10-3)   364/4724 (8:7)	Subgroups	PU	LABG		HR (95% CI)	p-value	p-value
Female   152/1373 (12:7)   119/1371 (10:6)   1.23 (10:7): 50   0.0854     Age at Baseline   265   200/2971 (8:0)   160/2940 (6:4)   1.23 (10:01-151)   0.0534   0.98     G5 or older   339/2782 (14:8)   277/2825 (12:5)   1.19 (10:2-1:40)   0.0156   0.43     Sody mass index   1.23 (10:01-151)   0.0156   0.43   0.057   0.43     G3 or one or 148/1548 (12:1)   106/1558 (8:6)   1.35 (10:5-1:73)   0.057   0.25     No   145/1859 (9:1)   103/1835 (6:6)   1.37 (10:6-1:76)   0.014   0.0527   0.25     No   145/1859 (9:1)   103/1835 (6:6)   1.19 (10:2-1:39)   0.0272   0.76     No   123 (10:6)   1.19 (10:2-1:39)   0.027   0.76     No   127/1744 (11:6)   185/1271 (10:7)   1.24 (10:0-1:34)   0.052   0.057     No   261/3538 (8:7)   252/3594 (8:4)   1.02 (0.86:1-21)   0.81   0.0051   0.0052   0.057     Version   75/242 (20:7)   58/440 (16:0)   1.21 (10:7)   1.21 (10:7)   0.0052   0.97   0.0652   0.97     No   1	Sex						
sqe at Baseline     123 (1-00-1-51)   0.0534   0.98     65 or older   339/782 (148)   277/2825 (12-5)   19 (102-1-40)   0.0284   0.0284     300 more   148/1548 (12-1)   0.06/1558 (8-6)   1-00 (1-04-1-40)   0.0155   0.43     30 or more   148/1548 (12-1)   106/1558 (8-6)   1-00 (1-04-1-40)   0.0155   0.43     4ypertension	Male	387/4380 (10-7)	318/4394 (8.8)	. <b>⊢</b> ← −1	1.20 (1.03-1.39)	0.0181	0.82
< 65	Female	152/1373 (12-7)	119/1371 (10.6)	H <del></del> +I	1.23 (0.97-1.57)	0.0854	
65 or older   393/2782 (14.8)   277/2825 (12.5)   119 (102.140)   0.0284     Sody mass index   304/3953 (9.4)   1-20 (104.140)   0.015   0.43     30 or more   148/1548 (12.2)   304/3953 (9.4)   1-20 (104.140)   0.015   0.43     30 or more   148/1548 (12.2)   332/3913 (10.6)   1-16 (1.00-1.34)   0.0527   0.254     No   145/1859 (9.1)   103/1835 (6.6)   1-19 (102.1-38)   0.027   0.76     Hypertension   119 (102.1-30)   0.027   0.76     Yes   054/3982 (11.0)   288/3862 (9.1)   1.19 (102.1-38)   0.027   0.76     No   124 (120.17)   148/1873 (9.5)   1.24 (120.17)   0.001   0.0077     Poison   276/2215 (15.7)   125/2171 (10.7)   1.24 (120.17)   0.001   0.001     No   261/353 (8.7)   25/354 (8.4)   1.21 (105.1-38)   0.002   0.001     Prior mozordial infort/er   135 (105.1)   1.24 (100.17)   1.24 (100.1-30)   0.004   0.001     Yes   183/1438 (14.2)   16/1471 (11.6)   1.22 (103.1-140)   0.018   0.0186   0.018   0.018	Age at Baseline						
Sody mass index     < 30	< 65	200/2971 (8.0)	160/2940 (6-4)	<b>⊢</b> •−1	1.23 (1.00-1.51)	0.0534	0.98
< 30	65 or older	339/2782 (14-8)	277/2825 (12.5)	<u>¦+</u> i	1.19 (1.02-1.40)	0.0284	
30 or more   148/1548 (12-1)   106/1558 (8-6)   1-35 (105-173)   0.0179     ivpertension   126 (100-1-34)   0.0527   0.25     No   145/1859 (9-1)   0.30 (133 (6-6)   1-37 (106-17-6)   0.0144     ivperlipidemia   129 (100-1-34)   0.0527   0.25     No   173/1744 (11-6)   288/3862 (9-1)   1-9 (102-1-39)   0.0272   0.76     No   173/1744 (11-6)   148/1873 (9-5)   1-24 (100-155)   0.0527   0.0077     No   21/3538 (8.7)   252/3594 (8-4)   1-9   1-02 (086-121)   0.81     eripheral vascular discurst   1-94 (120-1-74)   0.0001   0.0077     No   21/3538 (8.7)   252/3594 (8-4)   1-9   1-02 (086-121)   0.81     eripheral vascular discurst   1-94 (120-1-74)   0.0001   0.0077     No   318/4734 (10-6)   346/4724 (8.7)   1-94 (120-1-139)   0.00869   0.66     No   318/3700 (10-2)   257/3739 (8-4)   1-94 (1097-150)   0.0852   0.97     No   318/300 (10-2)   257/3739 (8-4)   1-94 (1097-150)   0.0852   0.97     No <td>Body mass index</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Body mass index						
Augertension     Yes   391/3880 (12-2)   332/3913 (10-6)   I -16 (1-00-1-34)   0.0527   0.25     No   145/1859 (9-1)   103/1835 (6-6)   I -19 (1-02-1-39)   0.0272   0.76     typertension   787   364/3982 (11-0)   288/3862 (9-1)   I -19 (1-02-1-39)   0.0272   0.76     No   173/1744 (1-6)   148/1873 (9-5)   I -24 (1-00-1-50)   0.0021   0.0077     Objects mellitus     Yes   278/2215 (15-7)   185/2171 (10-7)   I -4   1-44 (1-20-1-74)   0.0001   0.0077     No   261/3538 (8-7)   252/3594 (8-4)   I -4   1-35 (0-96-1-90)   0.0869   0.666     Performational state   75/424 (20-7)   58/440 (16-0)   I -4   1-35 (0-96-1-90)   0.0869   0.667     No   318/4734 (1-6)   346/4724 (8-7)   I -4   1-32 (1-05-1-39)   0.0014     Prior myocardial infartional state   313/438 (14-2)   146/1417 (11-6)   I -4   1-21 (1-97-150)   0.6852   0.977     No   318/3700 (10-2)   25/3739 (8-4)   I -4   I -44 (1-08-1430)   0.0182   0.971  <	< 30	373/3958 (11-2)	304/3953 (9-4)	ii	1.20 (1.04-1.40)	0.0156	0.43
Yes   391/380 (12-2)   332/3913 (10-6)   1-16 (1-00-1:34)   0.0527   0.25     No   145/1859 (9-1)   103/1835 (6-6)   1-37 (10-6-1:76)   0.0144     typerlipidemia   1-19 (1-02-1:39)   0.0272   0.76     No   173/1744 (11-6)   148/1873 (9-5)   1-19 (1-02-1:39)   0.0272   0.76     No   173/1744 (11-6)   148/1873 (9-5)   1-24 (1-00-1:55)   0.0527   0.0077     No   2178/2215 (15-7)   185/2171 (10-7)   1-44 (1-20-1:49)   0.0077   0.0077     No   261/3538 (8:7)   252/3594 (8-4)   1-02 (0.86-1:21)   0.81   0.0077     No   248/4734 (10-6)   346/4724 (8:7)   1-35 (0-96-1:90)   0.0869   0.666     No   428/4734 (10-6)   346/4724 (8:7)   1-21 (0-97-1:50)   0.0852   0.97     No   318/3100 (10-2)   257/3739 (8:4)   1-22 (1-03-1:44)   0.0180   0.0180     eft ventricular ejection   Fratom   1-14 (0-98-1:32)   0.097   0.65   0.052   0.97   0.012   0.91   0.21     20%   356/4447 (9-6)   311/4597 (8:3)   1-21 (0-97-1:54)	30 or more	148/1548 (12-1)	106/1558 (8-6)	¦⊢I	1.35 (1.05-1.73)	0.0179	
No   145/1859 (9·1)   103/1833 (6·6)   1-37 (106·1.76)   0.0144     Hyperlipidemia   119 (1.02-1.39)   0.0272   0.76     No   173/1744 (11-6)   148/1873 (9·5)   124 (1.00-1.55)   0.0527     Diabetes mellitus   124 (1.00-1.55)   0.0527   0.007N     No   251/3538 (8.7)   252/3594 (8.4)   102 (0.86-1.21)   0.81     Peripheral vascular disease   124 (1.00-1.55)   0.0089   0.666     No   428/4734 (10-6)   346/4724 (8.7)   1.35 (0.96-1.90)   0.0869   0.666     No   428/4734 (10-6)   346/4724 (8.7)   1.21 (1.05-1.39)   0.0094   0.0071     Prior myocardial infarction   1.22 (1.03-1.44)   0.0180   0.0180   0.977     No   318/3700 (10.2)   257/3739 (8.4)   1.14 (1.08-1.44)   0.0122   0.971     No   318/4300 (10.2)   257/3739 (8.4)   1.14 (1.08-1.44)   0.0122   0.971     S0   356/4447 (9.6)   311/4597 (8.3)   1.14 (0.98-1.32)   0.0974   0.655     30-49%   132/807 (19-3)   96/779 (15-1)   1.44 (1.08-1.44)   0.0122   0.971	Hypertension			1			
hyperlipidemia     Yes   364/3982 (11-0)   288/3862 (9-1)   119 (1-02-1-39)   0.0272   0.76     No   173/1744 (11-6)   148/1873 (9-5)   124 (1-00-1-55)   0.0527     Diabetes mellitus   124 (1-00-1-53)   0.0071   0.0071     No   213/1744 (11-6)   148/1873 (9-5)   144 (1-20-1-74)   0.0001   0.0077     No   261/3538 (8-7)   252/3594 (8-4)   102 (0-86-121)   0.81   0.0071     Vers   75/424 (20-7)   58/440 (16-0)   1-35 (0-96-1-90)   0.0869   0.666     No   428/4734 (10-6)   346/4724 (8-7)   1-21 (0-97-1-50)   0.0852   0.977     Ves   183/1438 (14-2)   146/1417 (11-6)   1-21 (0-97-1-50)   0.0852   0.977     No   318/3700 (10-2)   257/3739 (8-4)   1-44   1-21 (0-97-1-50)   0.0852   0.977     No   318/3700 (10-2)   257/3739 (8-4)   1-44 (1-48-184)   0.0122   0.974   0.655     30-49%   312/807 (19-3)   96/779 (15-1)   1-44 (1-08-184)   0.912   0.216     sesion complexity   SYNTAX score 0-22   105/1533 (8-1) <td>Yes</td> <td>391/3880 (12-2)</td> <td>332/3913 (10.6)</td> <td>i→i</td> <td>1.16 (1.00-1.34)</td> <td>0.0527</td> <td>0.22</td>	Yes	391/3880 (12-2)	332/3913 (10.6)	i→i	1.16 (1.00-1.34)	0.0527	0.22
Yes   364/3982 (11-0)   288/3862 (9-1)   11-19 (10-21-39)   0-0272   0-76     No   173/1744 (11-6)   148/1873 (9-5)   124 (1-00-1-55)   0-0527     Diabetes mellitus   1-24 (1-00-1-55)   0-0527   0-0071     No   261/3538 (8-7)   252/3594 (8-4)   1-04   1-24 (1-00-1-55)   0-0071     No   261/3538 (8-7)   252/3594 (8-4)   1-04   1-02 (0-86-1-21)   0-81     Peripheral vascular disease	No	145/1859 (9.1)	103/1835 (6-6)	·	1.37 (1.06-1.76)	0.0144	
No   173/1744 (11-6)   148/1873 (9-5)   1-24 (1-00-1-55)   0-0527     Diabetes mellitus	Hyperlipidemia			ł			
Diabetes mellitus     Yes   278/2215 (15-7)   185/2171 (10-7)   Image: colspan="2">1.44 (1-20-1-74)   0.0001   0.0077     No   261/3538 (8-7)   252/3594 (8.4)   Image: colspan="2">1.02 (0.86-1-21)   0.81     Peripheral vascular disease   75/424 (20-7)   58/440 (16-0)   Image: colspan="2">1.35 (0.96-1-90)   0.0869   0.66     No   428/4734 (10-6)   346/4724 (8-7)   Image: colspan="2">Image: colspan="2" Colspan="2	Yes	364/3982 (11.0)	288/3862 (9.1)	¦+1	1.19 (1.02-1.39)	0.0272	0.76
Yes   278/2215 (15-7)   185/2171 (10-7)   144 (120-174)   0-0001   0-0077     No   261/3538 (8-7)   252/3594 (8.4)   102 (0-86-1-21)   0.81     Peripheral vascular diseuterererererererererererererererererere	No	173/1744 (11-6)	148/1873 (9.5)	<b>⊢</b> ⊷−1	1.24 (1.00-1.55)	0.0527	
No   261/3538 (8-7)   252/3594 (8-4)   Image: Constraint of the second s	Diabetes mellitus						
Peripheral vascular disease     Yes   75/424 (20-7)   58/440 (16-0)     No   428/4734 (10-6)   346/4724 (8-7)     Prior myocardial infarction   1:21 (10-51-39)   0.0094     Yes   183/1438 (14-2)   146/1417 (11-6)   1-21 (0-97-1-50)   0.0852   0-97     No   318/3700 (10-2)   257/3739 (8-4)   1-22 (1-03-1-44)   0.0180   0.0180     eft ventricular ejection fraction    1-14 (0-98-1-32)   0-0974   0-65     30-49%   356/4447 (9-6)   311/4597 (8-3)   1-4   1-14 (0-98-1-32)   0-0974   0-65     30-49%   132/807 (19-3)   96/779 (15-1)   1-41 (1-08-1-84)   0-0122   -     <30%	Yes	278/2215 (15-7)	185/2171 (10.7)	<b>⊢</b> ⊷−1	1.44 (1.20-1.74)	0.0001	0.0077
Yes   75/424 (20.7)   58/440 (16-0)   1.35 (0.96-1:90)   0.0869   0.66     No   428/4734 (10-6)   346/4724 (8-7)   1.21 (1.05-1:39)   0.0094     Prior myocardial infarction   1.21 (0.97-1:50)   0.0852   0.97     No   318/3700 (10-2)   257/3739 (8-4)   1.22 (1.03-1:44)   0.0180     eft ventricular ejection   556/4447 (9-6)   311/4597 (8-3)   1.14 (0.98-1:32)   0.097   0.655     30-49%   356/4447 (9-6)   311/4597 (8-3)   1.14 (1.08-1:84)   0.0122   0.051     <300	No	261/3538 (8.7)	252/3594 (8-4)	<b>⊢</b> •	1.02 (0.86-1.21)	0.81	
No   428/4734 (10-6)   346/4724 (8-7)   I-21 (105-1-39)   0-0094     Prior myocardial infar-time   121 (0-97-1-50)   0-0852   0-97     No   318/3700 (10-2)   257/3739 (8-4)   1-22 (10-97-1-50)   0-0852   0-97     No   318/3700 (10-2)   257/3739 (8-4)   1-22 (10-97-1-50)   0-0852   0-97     eft ventricular ejection   raction   1-24 (10-98-1-32)   0-0074   0-65     30-49%   312/807 (19-3)   96/779 (15-1)   1-41 (10-81-84)   0-0122     <30%	Peripheral vascular d	isease		i			
Prior myocardial infarction     Yes   183/1438 (14-2)   146/1417 (11-6)     No   318/3700 (10-2)   257/3739 (8-4)     .eft ventricular ejection   raction     ≥50%   356/4447 (9-6)   311/4597 (8-3)     .ady   132/807 (19-3)   96/779 (15-1)     .ady   132/807 (19-3)   96/779 (15-1)     .ady   13/49 (57-3)   16/54 (34-4)     .ady   18/49 (57-3)   16/54 (34-4)     .ady   122 (10-71-134)   0-91     .ady   100/1585 (8-1)   1-02 (0-77-134)   0-91     .yntAx score 23-32   163/1677 (12-4)   122/1545 (10-9)   1-52 (1-15-202)   0-0029     .yntAx score >33   117/871 (16-5)   83/927 (11-6)   1-52 (1-15-202)   0-0029     .uss   .uss   .uss   .uss   .uss   .uss   .uss     .uss   .uss   .uss   .uss   .uss   .uss   .uss     .uss   .uss   .uss   .uss   .uss   .uss   .uss   .uss     .uss   .uss   .uss   .uss   .uss   .uss   .uss   .uss	Yes	75/424 (20-7)	58/440 (16.0)	+	1.35 (0.96-1.90)	0.0869	0.66
Yes   183/1438 (14-2)   146/1417 (11-6)   1-21 (0-97-1-50)   0.0852   0-97     No   318/3700 (10-2)   257/3739 (8-4)   1-22 (1-03-1-44)   0-0180     eft ventricular ejection   fraction   1-22 (1-03-1-44)   0-0180   0-0974   0-65     30-49%   356/4447 (9-6)   311/4597 (8-3)   1-44 (1-08-1-32)   0-0974   0-65     30-49%   132/807 (19-3)   96/779 (15-1)   1-44 (1-08-1-84)   0-0122   0-021     <30%	No	428/4734 (10.6)	346/4724 (8.7)	¦⊷⊷i	1.21 (1.05-1.39)	0.0094	
No   318/3700 (10·2)   257/3739 (8·4)   Image: constraint of the second	Prior myocardial infa	rction					
eff ventricular ejection   s36/4447 (9-6)   311/4597 (8-3)   1-14 (0-98-1-32)   0-0974   0-65     30-49%   132/807 (19-3)   96/779 (15-1)   1-41 (1-08-1-84)   0-0122     <30%	Yes	183/1438 (14-2)	146/1417 (11.6)	<b>i</b> —	1.21 (0.97-1.50)	0.0852	0.97
\$250%   356/4477 (9-6)   311/4597 (8-3)   1-14 (0-98-1-32)   0-0974   0-65     30-49%   132/807 (19-3)   96/779 (15-1)   1-41 (1-08-1-84)   0-0122   0-074   0-65     <30%	No	318/3700 (10-2)	257/3739 (8-4)	·	1.22 (1.03-1.44)	0.0180	
30-49%   132/807 (19·3)   96/779 (15·1)   1-41 (1·08-1·84)   0-0122     <30%	Left ventricular ejecti	on fraction		1			
< <tr>     &lt;30%     18/49 (57·3)     16/54 (34·4)     1-25 (0-64-2·46)     0-52       esion complexity     1-02 (0-77-1·34)     0-91     0-21       SYNTAX score 0-22     105/1533 (8·8)     1000/1585 (8·1)     1-02 (0-77-1·34)     0-91     0-21       SYNTAX score 23-32     163/1677 (12·4)     122/1545 (10·9)     1-4     1-52 (1·15-2·02)     0-0029       SYNTAX score &gt;33     117/871 (16·5)     83/927 (11·6)     1-2     3     1-52 (1·15-2·02)     0-0029       0.5     1     2     3     3     1-2     3     1-52 (1·15-2·02)     0-0029</tr>	≥50%	356/4447 (9.6)	311/4597 (8·3)	l <del>¦ </del> ♦ I	1.14 (0.98-1.32)	0.0974	0.65
Lesion complexity SYNTAX score 0-22 105/1533 (8-8) 100/1585 (8-1) 1-02 (0-77-1-34) 0-91 0-21 SYNTAX score 23-32 163/1677 (12-4) 122/1545 (10-9) 1-20 (0-94-1-51) 0-14 SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR Favors CABG	30-49%	132/807 (19.3)	96/779 (15.1)		1.41 (1.08-1.84)	0.0122	
SYNTAX score 0-22   105/1533 (8-8)   100/1585 (8-1)   1-02 (0-77-1-34)   0-91   0-21     SYNTAX score 23-32   163/1677 (12-4)   122/1545 (10-9)   1-20 (0-94-1-51)   0-14     SYNTAX score >33   117/871 (16-5)   83/927 (11-6)   1-52 (1-15-2-02)   0-0029     0.5   1   2   3     Favors PCI   HR	<30%	18/49 (57-3)	16/54 (34-4)	⊢––––––	1.25 (0.64-2.46)	0.52	
SYNTAX score 23-32   163/1677 (12-4)   122/1545 (10-9)   1   1   1-20 (0-94-1-51)   0-14     SYNTAX score >33   117/871 (16-5)   83/927 (11-6)   1   1-52 (1-15-2-02)   0-0029     0.5   1   2   3     Favors PCI   HR   Favors CABG	Lesion complexity			i			
SYNTAX score >33 117/871 (16-5) 83/927 (11-6) 1-52 (1-15-2-02) 0-0029 0.5 1 2 3 Favors PCI HR Favors CABG	SYNTAX score 0-22	105/1533 (8.8)	100/1585 (8.1)	⊢ <b>⊢</b>	1.02 (0.77-1.34)	0.91	0.21
05 1 2 3 Favors PCI HR Favors CABG	SYNTAX score 23-32	163/1677 (12-4)	122/1545 (10.9)	ı <b>¦</b> →→→	1.20 (0.94-1.51)	0-14	
Favors PCI HR Favors CABG	SYNTAX score >33	117/871 (16.5)	83/927 (11.6)	·	1.52 (1.15-2.02)	0.0029	
Favors PCI HR Favors CABG			0.5	1 2	7		
(95%CI)							
(00/00/)				(95%CI)			

ct2017



#### Diabetes No






t2017




#### **Stroke after CABG and PCI**








## Stroke after CABG or PCI Landmark analysis



2017



#### Stroke CABG and PCI Diabetes versus non-Diabetes



t2017



#### Conclusions pooled analysis of 11,518 patients from 11 randomized trials

Largest analysis of patients randomly assigned to PCI with stents or CABG

Mortality significantly lower with CABG in patients with multivessel disease and diabetes, and high coronary lesion complexity

Patients with left main disease and lower coronary lesion complexity have comparable survival with PCI and CABG

Stroke risk is higher in patients with diabetes undergoing CABG



